UTHR

United Therapeutics Corp

$554.73

-0.78%
Nov 20, 2026
Bobby Quantitative Model
United Therapeutics Corp is a commercial-stage biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH), a rare, progressive disease characterized by abnormally high blood pressure in the lungs' arteries. Its portfolio is anchored in the prostacyclin pathway — most of its products are built around the molecule treprostinil — and includes Tyvaso DPI (its largest revenue driver), Remodulin, Orenitram, Adcirca, and the oncology drug Unituxin, sold almost entirely in the United States. The company occupies a leadership position in PAH with a deeply entrenched, high-margin franchise, but it faces intensifying competitive pressure from Liquidia's Yutrepia and other entrants, making the durability of its treprostinil moat the central debate. The current investor narrative is dominated by a favorable patent-litigation outcome that reduced near-term competitive risk, FDA acceptance of the ralinepag NDA (a next-generation IP receptor agonist that could extend the franchise beyond treprostinil), and positive Phase 3 Tyvaso data in a new lung indication that opens a potential label-expansion runway — all set against a backdrop of decelerating top-line growth and a stock that has re-rated sharply higher over the past year.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Moderna

Moderna

MRNA

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis

BobbyInvestment Opinion: Should I buy UTHR Today?

Rating: Buy (accumulate on weakness). United Therapeutics pairs a fortress balance sheet (debt-to-equity of 0.0053, current ratio of 6.60, $1.19 billion of cash) and $867.2 million of TTM free cash flow with a 16.17x trailing PE that sits well below the 20-30x range typical of profitable large-cap biotech, while the 12 Buy / 2 Hold / 1 Sell consensus and $687.14 average target imply about +16.2% upside from $591.17. The core thesis is that a discounted multiple already prices in competitive erosion that has not yet appeared in the numbers, and that ralinepag (NDA accepted) plus Tyvaso label expansion can re-accelerate growth before Liquidia's Yutrepia meaningfully dents the treprostinil franchise.

Supporting evidence is concrete: gross margin of 88.1% and a 31.06% net margin on Q3 2026 revenue of $832.5 million remain exceptional, EV/EBITDA of 11.03x and a PEG of 1.16 are modest for an 18.81% ROE business, and 3.04x price-to-book is reasonable against that return profile. The balance sheet carries essentially no leverage (interest coverage above 100x), and management repurchased $500 million of stock in Q3 2026 alone after $1.5 billion in Q1, funded entirely from internal cash — a valuation floor and a signal of confidence. Momentum corroborates the fundamental case: the stock is up 27.88% over the trailing year and 18.30% over three months, outperforming SPY by 15.61 and 21.13 points respectively.

The risks that could invalidate this view are revenue growth stalled at 4.13% year-over-year, extreme Tyvaso concentration ($503.8 million of an $832.5 million quarter), and margin compression as R&D stepped up to $279.2 million from $127.5 million a year earlier, cutting net margin to 31.06% from 42.36%. This Buy would downgrade to Hold if revenue growth turns negative or Tyvaso share loss to Yutrepia becomes visible in quarterly scripts, and to Sell if ralinepag launch or Tyvaso label expansion disappoints while R&D stays elevated. On balance the stock is modestly undervalued relative to its own history (16.17x versus 22-24x in 2022) and to profitable biotech peers, but it is not deeply cheap — the discount is real yet partly earned by decelerating growth.

Sign up to view all

UTHR 12-Month Price Forecast

The forward view is constructive but not euphoric: a 16.17x trailing PE on an 88.1% gross-margin franchise with $867.2 million of TTM free cash flow leaves room for multiple expansion if ralinepag and Tyvaso label expansion deliver, which is why the base case (55% probability) targets $650-$720 around the $687.14 consensus. The central risk is that 4.13% revenue growth and Tyvaso concentration mean the discount is partly earned, and the 2x analyst target spread ($390 to $850) confirms genuine disagreement about the post-patent-cliff trajectory. The low 0.48 beta and fortress balance sheet support position sizing, but the roughly 7% single-day gap on November 5, 2026 is a reminder that idiosyncratic news, not macro, drives drawdowns here. I would upgrade to high confidence if Tyvaso quarterly revenue re-accelerates above $520 million with no Yutrepia share loss, and downgrade to neutral if growth turns negative or net margin stays below 31% for two consecutive quarters.

Historical Price
Current Price $554.73
Average Target $685.00
High Target $850.00
Low Target $390.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $687.14 and implied upside of +23.9% versus the current price.

Average Target

$687.14

15 analysts

Implied Upside

+23.9%

vs. current price

Analyst Count

15

covering this stock

Price Range

$390 - $850

Analyst target range

Buy
12 (80%)
Hold
2 (13%)
Sell
1 (7%)

Coverage is solid with 14 analysts, and sentiment is decisively bullish: 12 Buy ratings, 2 Hold, and 1 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.73 (where 1.0 is a strong buy). The average target price of $687.14 implies roughly +16.2% upside from the current $591.17, a meaningful but not euphoric gap that suggests analysts see continued appreciation without extreme optimism. The consensus leans clearly bullish, and the recent institutional ratings flow supports this — BTIG upgraded to Buy from Neutral on October 1, and firms including Wells Fargo, TD Cowen, RBC, and JP Morgan have reiterated Overweight/Buy/Outperform ratings through early November, with no downgrades in the visible recent history.

The target range is wide — from a low of $390.00 to a high of $850.00, a spread of more than 2x — signaling meaningful disagreement about the franchise's trajectory. The high target of $850 (roughly +44% upside) likely assumes successful ralinepag commercialization, Tyvaso label expansion into new lung indications, and multiple expansion as the market gains confidence in the post-patent-cliff growth story. The low target of $390 (about -34% downside) likely prices in aggressive share loss to Liquidia's Yutrepia and other PAH competitors, margin compression from rising R&D, and a de-rating toward the low end of the historical PE band. The wide dispersion, combined with the low beta of 0.48 and the recent 7% single-day gap, argues for disciplined position sizing and attention to event risk around pipeline catalysts and competitive developments.

Drowning in data?

Find the real signal!

Bulls vs Bears: UTHR Investment Factors

The bull case currently has stronger evidence: a fortress balance sheet, 88% gross margins, a 16.17x PE at a clear discount to profitable biotech peers, $867.2 million of TTM free cash flow, aggressive buybacks, and a pipeline (ralinepag NDA accepted, Tyvaso label expansion) that addresses the central competitive threat. The bear case rests on decelerating 4.13% revenue growth, heavy Tyvaso concentration, and margin compression from R&D, but these are largely known and already reflected in the discounted multiple. The single most important tension is whether ralinepag and Tyvaso label expansion can re-accelerate growth before Liquidia's Yutrepia and other PAH entrants erode the treprostinil franchise — if the pipeline delivers, the discount closes; if competition bites first, the low-end $390 target becomes credible. Analyst sentiment (12 Buy, 2 Hold, 1 Sell, average target $687.14) and the stock's 27.88% one-year outperformance suggest the market is leaning toward the bull resolution, but the 2x target spread argues for disciplined position sizing around catalysts.

Bullish

  • Fortress balance sheet, minimal leverage: Debt-to-equity is just 0.0053, the current ratio is 6.60, and interest coverage exceeds 100x, meaning essentially zero financial risk. With $1.19 billion of cash and $867.2 million of TTM free cash flow, the company can self-fund pipeline development and buybacks without dilution.
  • Deep valuation discount to biotech peers: At a trailing PE of 16.17x and EV/EBITDA of 11.03x, UTHR trades well below the 20-30x PE range typical of profitable large-cap biotech. The PEG of 1.16 and 3.04x price-to-book against an 18.81% ROE suggest the market is pricing in competitive erosion that has not yet materialized in the numbers.
  • Pipeline catalysts de-risk the franchise: FDA acceptance of the ralinepag NDA and positive Phase 3 Tyvaso data in a new lung indication open a label-expansion runway beyond treprostinil. The favorable patent-litigation outcome reduced near-term competitive risk, and the stock's 12.6% single-day jump on October 1 reflects how much the market values these catalysts.
  • Exceptional margins and capital returns: Gross margin of 88.1% and a 31.06% net margin on Q3 2026 revenue of $832.5 million remain far above typical biotech peers. Management repurchased $500 million of stock in Q3 2026 alone (after $1.5 billion in Q1), funded entirely from internal cash, providing a valuation floor and signaling confidence.

Bearish

  • Revenue growth has stalled at low single digits: Q3 2026 revenue of $832.5 million grew only 4.13% year-over-year, and quarterly revenue has plateaued around $780-$832 million through 2026. The core treprostinil franchise is maturing, and the forward PE of 17.09x sitting above the trailing 16.17x implies the market expects no meaningful near-term earnings growth.
  • Extreme concentration in Tyvaso: Tyvaso at $503.8 million accounts for the majority of revenue, with Orenitram ($145.0M) and Remodulin ($122.0M) behind it, while Adcirca ($4.5M) and Unituxin ($52.3M) are immaterial. The entire investment case hinges on Tyvaso's durability against Liquidia's Yutrepia and other PAH entrants.
  • Margin compression from rising R&D: Net margin fell to 31.06% in Q3 2026 from 42.36% in Q3 2025 and 46.10% in Q4 2025, driven by R&D stepping up to $279.2 million from $127.5 million a year earlier. If pipeline spending keeps climbing without offsetting revenue, earnings could contract even as the top line grows modestly.
  • Wide analyst dispersion signals uncertainty: Targets range from $390 (-34%) to $850 (+44%), a spread of more than 2x, reflecting genuine disagreement about the post-patent-cliff trajectory. The low target prices in aggressive share loss to Yutrepia and a de-rating toward the low end of the historical PE band.

UTHR Technical Analysis

UTHR is in a sustained, powerful uptrend, with the current price of $591.17 representing a 27.88% gain over the trailing year and a 19.01% advance year-to-date, comfortably outperforming the S&P 500's 12.27% and 10.62% respective returns. At $591.17, the stock sits at roughly 85.4% of its 52-week range (low $455.63 to high $614.23), positioning it in the upper quartile — a zone that reflects strong momentum but also leaves limited headroom before the stock tests its prior high. The relative strength readings reinforce this leadership, with 1-year relative strength of +15.61 and 3-month relative strength of +21.13 versus SPY, indicating the stock is not merely rising but actively outperforming the market by a widening margin.

Short-term momentum is clearly accelerating: the stock is up 9.47% over the past month and 18.30% over three months, both sharply ahead of the 1-year pace and well above SPY's -2.26% and -2.83% respective moves over the same windows. This acceleration follows a notable volatility episode — a sharp single-day drop from $608.49 on November 4 to $565.72 on November 5 (a roughly 7% gap down, likely tied to the Q3 print) that was rapidly absorbed, with the stock recovering to $591.17 by November 13. That V-shaped recovery is a bullish tell, suggesting buyers stepped in aggressively on the dip; however, the 6-month change of just 3.97% versus the 3-month gain of 18.30% reveals that most of the recent strength is concentrated in the last quarter, meaning the move is relatively fresh rather than a mature, extended trend.

Key technical levels are well defined: resistance sits at the 52-week high of $614.23, roughly 3.9% above the current price, and a decisive breakout above that level would confirm the uptrend and likely invite momentum-driven buying. Support is anchored by the 52-week low of $455.63 (about 23% below current levels), with intermediate support around the $540–$565 zone where the stock consolidated in October and where the November gap-down was absorbed. The beta of 0.48 is a critical risk-management input — it implies the stock is roughly 52% less volatile than the broader market, consistent with its defensive, cash-generative biotech profile, which means position sizing can be larger for a given risk budget, though the recent 7% single-day move is a reminder that idiosyncratic, news-driven gaps can overwhelm the low beta. The maximum drawdown of -20.87% over the period further underscores that despite low market correlation, stock-specific event risk remains material.

Beta

0.48

0.48x market volatility

Max Drawdown

-20.9%

Largest decline past year

52-Week Range

$456-$614

Price range past year

Annual Return

+16.9%

Cumulative gain past year

PeriodUTHR ReturnS&P 500
1m-1.6%-9.7%
3m+8.1%-9.9%
6m-2.4%-7.5%
1y+16.9%+4.7%
ytd+11.7%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

UTHR Fundamental Analysis

Revenue growth has decelerated to a low single-digit pace: Q3 2026 revenue of $832.5 million grew just 4.13% year-over-year versus $799.5 million in Q3 2025, a marked slowdown from the double-digit trajectory the franchise enjoyed in earlier periods. The multi-quarter trend shows revenue essentially plateauing around $780–$832 million per quarter through 2026 ($781.5M in Q1, $783.3M in Q2, $832.5M in Q3) after a 2025 run-rate near $790–$800 million, implying the core treprostinil franchise is maturing. Segment data confirms concentration risk: Tyvaso at $503.8 million accounts for the majority of revenue, followed by Orenitram at $145.0 million and Remodulin at $122.0 million, while Adcirca ($4.5M) and Unituxin ($52.3M) are immaterial — meaning the investment case hinges almost entirely on Tyvaso's durability and the ralinepag/indication-expansion pipeline.

Profitability remains exceptional for a biotechnology company: Q3 2026 net income was $258.6 million on a 31.06% net margin, with a gross margin of 88.1% ($733.4 million gross profit) and an operating margin of 36.97%. Margins have compressed modestly from the 2025 peak — Q3 2025 net margin was 42.36% and Q4 2025 was 46.10% — driven largely by a step-up in R&D spending to $279.2 million in Q3 2026 from $127.5 million a year earlier, reflecting pipeline investment in ralinepag and Tyvaso label expansion. The 88%+ gross margin is characteristic of a specialty-pharma franchise with pricing power and low cost of goods, and even at the compressed 31% net margin the company remains far more profitable than the typical clinical-stage or even commercial biotech peer.

The balance sheet is fortress-like: debt-to-equity is a negligible 0.0053, the current ratio is a very strong 6.60, and interest coverage exceeds 100x, meaning the company carries essentially no leverage risk. Free cash flow is robust at $867.2 million TTM, and Q3 2026 operating cash flow of $306.5 million comfortably funded $180.7 million of capex (much of it likely tied to the company's organ-manufacturing buildout) while still leaving $125.8 million of quarterly FCF. Management is aggressively returning capital — $500 million of stock repurchased in Q3 2026 alone, following $1.5 billion in Q1 2026 — funded entirely from internal cash generation, which signals confidence and provides a valuation floor. ROE of 18.81% and ROA of 10.91% confirm efficient capital deployment, and with $1.19 billion of cash on hand, the company has ample liquidity to fund pipeline development without external financing.

Quarterly Revenue

$832500000.0B

2026-09

Revenue YoY Growth

+4.1%

YoY Comparison

Gross Margin

88.1%

Latest Quarter

Free Cash Flow

$867200000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Adcirca
Orenitram
Product and Service, Other
Remodulin
Tyvaso
Unituxin

Open an Account, get $2 TSLA now!

Valuation Analysis: Is UTHR Overvalued?

Because United Therapeutics is solidly profitable (Q3 2026 net income of $258.6 million), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 16.17x against a forward PE of 17.09x — an unusual configuration where the forward multiple is slightly higher than the trailing, implying the market is not pricing in meaningful near-term earnings growth (consensus EPS estimates of $51.24 appear to reflect a different share-count or adjusted basis than the reported quarterly figures, so the forward multiple should be treated with caution). The PEG ratio of 1.16 suggests the stock is reasonably priced relative to its growth rate, and the EV/EBITDA of 11.03x is modest for a high-margin specialty-pharma franchise.

Against the broader biotechnology sector — where profitable, large-cap names typically command PE multiples in the 20–30x range and unprofitable peers trade on revenue multiples — UTHR's 16.17x trailing PE represents a meaningful discount, likely reflecting the market's concern about PAH competitive encroachment and the maturing core franchise. The PS ratio of 6.78x and EV/Sales of 7.25x are also moderate for an 88% gross-margin business, while the price-to-book of 3.04x is reasonable given the 18.8% ROE. The discount appears at least partially justified by the decelerating 4.13% revenue growth, but the 31% net margin and fortress balance sheet argue the discount is wider than the fundamentals warrant — a classic value-versus-growth tension.

On a historical basis, the stock's valuation has re-rated upward: the PE ratio stood at 13.56x in Q3 2025 and 14.57x in Q4 2025, versus 16.17x today, placing the current multiple in the upper portion of its recent band but still well below the 22–24x levels seen in 2022 and early 2026. The PS ratio of 6.78x compares favorably to historical readings that ranged from roughly 16x to 33x in the historical ratios data (though those figures appear to use a different revenue base), and the PB of 3.04x is near the middle of its multi-year range. The takeaway is that the stock is not cheap on an absolute historical basis but is far from stretched — the market is pricing in modest expectations, leaving room for multiple expansion if ralinepag or the Tyvaso label expansion delivers upside surprises.

PE

16.2x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 9x~24x

vs. Industry Avg

29.3x

Industry PE ~29.3x*

EV/EBITDA

11.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on concentration and margin trajectory rather than solvency. Tyvaso at $503.8 million dominates a $832.5 million quarterly revenue base, so any share loss to Liquidia's Yutrepia or pricing pressure hits the majority of the franchise directly, and revenue growth has already decelerated to 4.13% year-over-year. R&D jumped to $279.2 million in Q3 2026 from $127.5 million a year earlier, compressing net margin to 31.06% from 42.36%, and if pipeline spending continues rising while the core plateaus around $780-$832 million per quarter, earnings could decline even with modest top-line growth. The mitigating factor is a near-debt-free balance sheet (debt-to-equity 0.0053, current ratio 6.60) and $867.2 million of TTM free cash flow, which means these are growth-investment risks, not liquidity risks.

Market and competitive risks are the dominant external threat. The PAH space is intensifying, with Liquidia's Yutrepia showing strong commercial momentum and Insmid/other entrants competing for the same patients, and the stock's wide $390-$850 analyst target range reflects genuine disagreement about how much share UTHR retains. Valuation compression is a real possibility: the PE has already re-rated from 13.56x in Q3 2025 to 16.17x today, and if growth stays in the low single digits the multiple could revert toward the low end of its historical band rather than expand toward the 22-24x seen in 2022. The 0.48 beta limits broad market correlation, but the roughly 7% single-day gap on November 5 (from $608.49 to $565.72) around the Q3 print shows that company-specific news, not macro, is the real driver of drawdowns here.

The worst-case scenario is a competitive share-loss spiral combined with pipeline disappointment: Yutrepia and other entrants take meaningful Tyvaso volume, ralinepag launch or Tyvaso label expansion underdelivers, and R&D spending stays elevated, compressing margins and forcing a de-rating toward the low end of the historical PE band. In that chain, the stock could fall toward the analyst low target of $390, roughly -34% from the current $591.17, and a retest of the 52-week low of $455.63 would represent about -23%. The -20.87% maximum drawdown already observed over the period is a realistic template for a single adverse event, meaning investors should size positions assuming a 20-35% drawdown is possible if the competitive and pipeline narrative turns negative.

FAQ

The most severe risk is competitive erosion of the Tyvaso franchise, which at $503.8 million dominates an $832.5 million quarter, and Liquidia's Yutrepia is showing accelerating commercial momentum per its Q3 2026 earnings call. Second is margin compression: R&D jumped to $279.2 million in Q3 2026 from $127.5 million a year earlier, cutting net margin to 31.06% from 42.36%, and if spending stays elevated while revenue plateaus around $780-$832 million, earnings could contract. Third is pipeline execution risk — the ralinepag NDA is accepted but not approved, and a launch miss or Tyvaso label-expansion delay would push out the growth story and could drive a de-rating toward the $390 low target. Fourth is event-driven volatility despite the 0.48 beta: the stock gapped about 7% in a single day on November 5, 2026, and the -20.87% maximum drawdown shows company-specific news, not macro, is the real driver of losses here.

The base case (55% probability) targets $650-$720, centered on the $687.14 analyst average (+16.2%), assuming Tyvaso holds above roughly $500 million per quarter, ralinepag launches orderly, R&D moderates, and the multiple holds near 16-18x. The bull case (25%) targets $780-$850, near the $850 high target (+44%), if ralinepag and Tyvaso label expansion re-accelerate growth into the high single or low double digits and the multiple re-rates toward 22-24x. The bear case (20%) targets $390-$456, anchored on the $390 analyst low (-34%) and the $455.63 52-week low (-23%), if Yutrepia takes meaningful volume and margins stay near 31%. The base case is most likely, and its key assumption is that competitive erosion stays gradual and the pipeline delivers on schedule. The wide $390-$850 spread reflects genuine disagreement about the post-patent-cliff trajectory.

The stock looks modestly undervalued rather than cheap. At a 16.17x trailing PE and 11.03x EV/EBITDA, UTHR trades well below the 20-30x PE range typical of profitable large-cap biotech, and its PEG of 1.16 and 3.04x price-to-book against an 18.81% ROE support that discount. Against its own history the multiple has re-rated from 13.56x in Q3 2025 and 14.57x in Q4 2025 to 16.17x today, still below the 22-24x seen in 2022, so it sits in the upper part of its recent band but far from stretched. The forward PE of 17.09x sitting slightly above the trailing multiple implies the market expects no meaningful near-term earnings growth, which is consistent with 4.13% revenue growth. What the market is pricing in is competitive erosion that has not yet shown up in the numbers; if ralinepag and Tyvaso label expansion deliver, the discount should narrow toward the $687.14 consensus.

On a risk/reward basis the setup is favorable but not one-sided. The stock at $591.17 sits about 16.2% below the $687.14 average analyst target, with 12 of 14 analysts rating it Buy, while the 16.17x trailing PE and 11.03x EV/EBITDA are modest for an 88.1% gross-margin, $867.2 million free-cash-flow business. The downside is real: the $390 analyst low target implies -34%, and a retest of the $455.63 52-week low would be about -23%, driven by Yutrepia share loss or a ralinepag disappointment. The low 0.48 beta and near-zero leverage (debt-to-equity 0.0053) make the position easier to size, but the roughly 7% single-day gap on November 5, 2026 shows idiosyncratic event risk can hit quickly. It is a good buy for patient investors comfortable with a 20-35% drawdown scenario who want defensive healthcare exposure with a pipeline kicker; it is less suited to investors needing near-term growth acceleration, given 4.13% revenue growth.

UTHR fits a long-term holding profile better than a trading vehicle. It is a mature, profitable franchise with 4.13% revenue growth, an 88.1% gross margin, $867.2 million of TTM free cash flow, and no dividend (payout ratio 0), so total return depends on earnings growth plus multiple expansion rather than income. The 0.48 beta and fortress balance sheet (current ratio 6.60, debt-to-equity 0.0053) make it a defensive core healthcare position, and the $500 million Q3 2026 buyback after $1.5 billion in Q1 provides a valuation floor over time. However, the roughly 7% single-day gap on November 5, 2026 and the -20.87% maximum drawdown mean short-term holders face real event risk around earnings and pipeline news. A minimum holding period of 18-24 months is reasonable to let the ralinepag launch and Tyvaso label expansion play out, with position sizing that assumes a 20-35% drawdown is possible.